Romyelocel-L

Drug Profile

Romyelocel-L

Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant Therapeutics

Latest Information Update: 13 Jan 2015

Price : $50

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia
  • Phase I Haematological disorders
  • Preclinical Acute radiation syndrome

Most Recent Events

  • 01 Dec 2014 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in USA (IV)
  • 31 Oct 2014 Cellerant Therapeutics plans a phase II trial for Neutropenia (Chemotherapy-induced) in USA (NCT02282215)
  • 11 Sep 2014 Cellerant receives $US47.5 million under existing contract with the US Biomedical Advanced Research and Development Authority (BARDA) for CLT 008 in neutropenia and acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top